1 le density is apparent only in S1 and S2 for antipain.

2 ation of a new analogue of antipain, deimino-antipain.

3 leupeptin (5 mM) and completely prevented by antipain (2.5 mM).

4  possesses interesting anti-inflammatory and antipain activities.

5                            The P1 arginyl of antipain also binds at this site, but the positive charg

6 e activity was most effectively inhibited by antipain and 4-(2-aminoethyl) benzenesulfonyl fluoride,

7                       The peptide aldehydes, antipain and chymostatin, form covalent adducts with the

8  Moreover, ColV-1 processing is inhibited by antipain and N-ethylmaleimide.

9 in, pancreatic trypsin inhibitor, leupeptin, antipain, and EDTA could not prevent histatin 5, stather

10                                  The CPD-WII antipain arginine model has a standard crystallographic

11               Antiviral and antiinflammatory-antipain assays have targeted various classes of chemica

12 ing, peptidic protease inhibitors, including antipain, chymostatin, leupeptin, elastatinal, and micro

13 g to the identification of a new analogue of antipain, deimino-antipain.

14 ex with the oligopeptide, protease-inhibitor antipain, giving detailed information on the enzyme acti

15 nyl fluoride (3 mm), leupeptin (100 microm), antipain (IC(50) = 2 microm), HgCl(2) (IC(50) = 500 micr

16                              Pefabloc SC and antipain inhibited the proteolytic activity of both fI a

17 ntration-dependent and could be inhibited by antipain, N-ethylmaleimide, EDTA, and EGTA.

18                     Opioid receptors mediate antipain responses in both the peripheral nervous system

19                            The inhibition by antipain suggested the presence of cysteine or serine pr

20            The bacterial producer of deimino-antipain was sequenced and the responsible biosynthetic